• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

描述转移性结直肠癌各疾病阶段的医疗护理。

Characterizing medical care by disease phase in metastatic colorectal cancer.

机构信息

Thomson Reuters, Cambridge, MA, and Washington, DC; and Amgen, Thousand Oaks, CA.

出版信息

J Oncol Pract. 2011 May;7(3 Suppl):25s-30s. doi: 10.1200/JOP.2011.000304.

DOI:10.1200/JOP.2011.000304
PMID:21886516
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3092457/
Abstract

PURPOSE

To characterize patterns of medical care by disease phase in patients with newly diagnosed metastatic colorectal cancer (mCRC).

METHODS

Patients with mCRC newly diagnosed between 2004 and 2008 were selected from a large US national commercially insured claims database and were observed from initial mCRC diagnosis to death, disenrollment, or end of study period (July 31, 2009), whichever occurred first. The observation period was divided into three distinct phases of disease: diagnostic, treatment, and death. Within each phase, patterns of medical care were examined by the mutually exclusive service categories of inpatient, emergency room (ER), outpatient office and facility, outpatient pharmacy, chemotherapy, and biologic therapy, as measured by estimation of aggregate and category costs per patient per month.

RESULTS

A total of 6,675 patients with newly diagnosed mCRC were analyzed. Mean age was 64.1 years; 55.5% were males. Mean costs per patient per month for diagnostic, treatment, and death phases were $16,895, $8,891, and $27,554, respectively. Inpatient care was the primary driver of medical care for both the diagnostic (41.7% of costs) and death (71.4% of costs) phases. The largest category of medical care for the treatment phase was outpatient care (45.0% of costs). Chemotherapy and biologic therapy accounted for 15.6% and 17.6% of costs in the treatment phase, respectively.

CONCLUSION

Substantial differences in patterns of medical care were found between mCRC disease phases. Inpatient care was the key driver of medical care in the diagnostic and death phases compared with outpatient care in the treatment phase.

摘要

目的

描述新诊断转移性结直肠癌(mCRC)患者各疾病阶段的医疗护理模式。

方法

从美国大型商业保险理赔数据库中选择 2004 年至 2008 年间新诊断为 mCRC 的患者,并在初始 mCRC 诊断至死亡、退出或研究结束(2009 年 7 月 31 日)期间进行观察,以先发生者为准。观察期分为疾病的三个不同阶段:诊断期、治疗期和死亡期。在每个阶段内,通过对患者每月每例的累计和分类成本进行评估,根据互斥的服务类别(住院、急诊室(ER)、门诊办公室和设施、门诊药房、化疗和生物治疗)来检查医疗护理模式。

结果

共分析了 6675 例新诊断为 mCRC 的患者。患者平均年龄为 64.1 岁,55.5%为男性。诊断、治疗和死亡期的患者每月每例的平均成本分别为 16895 美元、8891 美元和 27554 美元。在诊断期(41.7%的费用)和死亡期(71.4%的费用),住院治疗是医疗护理的主要驱动因素。治疗期医疗护理的最大类别是门诊护理(45.0%的费用)。化疗和生物治疗分别占治疗期费用的 15.6%和 17.6%。

结论

mCRC 各疾病阶段的医疗护理模式存在显著差异。与治疗期的门诊护理相比,住院治疗是诊断期和死亡期医疗护理的关键驱动因素。

相似文献

1
Characterizing medical care by disease phase in metastatic colorectal cancer.描述转移性结直肠癌各疾病阶段的医疗护理。
J Oncol Pract. 2011 May;7(3 Suppl):25s-30s. doi: 10.1200/JOP.2011.000304.
2
Characterizing medical care by disease phase in metastatic colorectal cancer.描述转移性结直肠癌各疾病阶段的医疗护理。
Am J Manag Care. 2011 May;17 Suppl 5 Developing:SP20-5.
3
Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer.估算新诊断转移性结直肠癌患者的护理费用。
Clin Colorectal Cancer. 2006 May;6(1):52-8. doi: 10.3816/CCC.2006.n.021.
4
Treatment patterns and metastasectomy among mCRC patients receiving chemotherapy and biologics.接受化疗和生物制剂治疗的 mCRC 患者的治疗模式和转移灶切除术。
Curr Med Res Opin. 2011 Jan;27(1):123-30. doi: 10.1185/03007995.2010.536912. Epub 2010 Dec 6.
5
Healthcare costs, treatment patterns, and resource utilization among pancreatic cancer patients in a managed care population.在医疗保险人群中,胰腺癌患者的医疗费用、治疗模式和资源利用情况。
J Med Econ. 2013 Dec;16(12):1379-86. doi: 10.3111/13696998.2013.848208. Epub 2013 Oct 18.
6
Impact of metastatic colorectal cancer stage and number of treatment courses on patient health care costs and utilization.转移性结直肠癌分期和治疗疗程数对患者医疗保健费用和利用的影响。
Postgrad Med. 2013 Mar;125(2):73-82. doi: 10.3810/pgm.2013.03.2642.
7
Corroboration of claims algorithm for second-line costs of metastatic colorectal cancer treatment with targeted agents.伴有靶向药物的转移性结直肠癌二线治疗的二线成本的主张验证算法。
J Med Econ. 2013 Aug;16(8):1071-81. doi: 10.3111/13696998.2013.813513. Epub 2013 Jul 5.
8
Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality.转移性乳腺癌女性患者接受化疗作为主要治疗方式的医疗费用。
BMC Cancer. 2011 Jun 15;11:250. doi: 10.1186/1471-2407-11-250.
9
Healthcare costs in patients with metastatic lung cancer receiving chemotherapy.转移性肺癌化疗患者的医疗费用。
BMC Health Serv Res. 2011 Nov 10;11:305. doi: 10.1186/1472-6963-11-305.
10
The economic burden of lung cancer and the associated costs of treatment failure in the United States.美国肺癌的经济负担及治疗失败的相关成本。
Lung Cancer. 2005 Nov;50(2):143-54. doi: 10.1016/j.lungcan.2005.06.005. Epub 2005 Aug 19.

引用本文的文献

1
A multi-center effectiveness comparison study of fruquintinib with constructed external control cohort of other targeted kinase inhibitors using real-world data in third-line treatment of metastatic colorectal cancer.一项使用真实世界数据对呋喹替尼与其他靶向激酶抑制剂构建的外部对照队列进行多中心疗效比较的研究,用于转移性结直肠癌的三线治疗。
Front Oncol. 2022 Nov 24;12:1044328. doi: 10.3389/fonc.2022.1044328. eCollection 2022.
2
Cost-effectiveness of adding Endocuff to standard colonoscopies for interval colorectal cancer screening.在间隔期结直肠癌筛查的标准结肠镜检查中添加Endocuff的成本效益。
Clinicoecon Outcomes Res. 2019 Jul 31;11:487-504. doi: 10.2147/CEOR.S201328. eCollection 2019.
3
Cost of Disease Progression in Patients with Metastatic Breast, Lung, and Colorectal Cancer.转移性乳腺癌、肺癌和结直肠癌患者的疾病进展成本。
Oncologist. 2019 Sep;24(9):1209-1218. doi: 10.1634/theoncologist.2018-0018. Epub 2019 Feb 22.
4
Risk of unplanned visits for colorectal cancer outpatients receiving chemotherapy: a case-crossover study.接受化疗的结直肠癌门诊患者计划外就诊的风险:一项病例交叉研究。
Support Care Cancer. 2014 Sep;22(9):2527-33. doi: 10.1007/s00520-014-2234-z. Epub 2014 Apr 13.

本文引用的文献

1
Systemic Therapy for Metastatic Colorectal Cancer: Patterns of Chemotherapy and Biologic Therapy Use in US Medical Oncology Practice.转移性结直肠癌的系统治疗:美国肿瘤医学实践中化疗和生物治疗的应用模式。
J Oncol Pract. 2010 Nov;6(6):301-7. doi: 10.1200/JOP.2010.000072.
2
Treatment patterns and metastasectomy among mCRC patients receiving chemotherapy and biologics.接受化疗和生物制剂治疗的 mCRC 患者的治疗模式和转移灶切除术。
Curr Med Res Opin. 2011 Jan;27(1):123-30. doi: 10.1185/03007995.2010.536912. Epub 2010 Dec 6.
3
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.随机、III 期临床试验:帕尼单抗联合氟尿嘧啶、亚叶酸钙和奥沙利铂(FOLFOX4)对比 FOLFOX4 一线治疗未经治疗的转移性结直肠癌患者:PRIME 研究。
J Clin Oncol. 2010 Nov 1;28(31):4697-705. doi: 10.1200/JCO.2009.27.4860. Epub 2010 Oct 4.
4
The Surgical Pathology of Rectal Cancer: President's Address.直肠癌的外科病理学:主席致辞
Proc R Soc Med. 1944 Feb;37(4):131-44. doi: 10.1177/003591574403700402.
5
Lifetime and treatment-phase costs associated with colorectal cancer: evidence from SEER-Medicare data.结直肠癌的终身成本和治疗阶段成本:来自监测、流行病学和最终结果-医疗保险数据的证据
Clin Gastroenterol Hepatol. 2009 Feb;7(2):198-204. doi: 10.1016/j.cgh.2008.08.034. Epub 2008 Sep 4.
6
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.贝伐单抗联合奥沙利铂、氟尿嘧啶和亚叶酸钙(FOLFOX4)用于既往治疗过的转移性结直肠癌:东部肿瘤协作组E3200研究结果
J Clin Oncol. 2007 Apr 20;25(12):1539-44. doi: 10.1200/JCO.2006.09.6305.
7
Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer.估算新诊断转移性结直肠癌患者的护理费用。
Clin Colorectal Cancer. 2006 May;6(1):52-8. doi: 10.3816/CCC.2006.n.021.
8
End-stage renal disease-associated managed care costs among patients with and without diabetes.患有和未患糖尿病的患者中与终末期肾病相关的管理式医疗费用。
Diabetes Care. 2004 Dec;27(12):2829-35. doi: 10.2337/diacare.27.12.2829.
9
Cost of illness associated with metastatic breast cancer.转移性乳腺癌的疾病成本。
Breast Cancer Res Treat. 2004 Jan;83(1):25-32. doi: 10.1023/B:BREA.0000010689.55559.06.
10
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.一项针对既往未接受治疗的转移性结直肠癌患者,比较氟尿嘧啶联合亚叶酸、伊立替康及奥沙利铂不同组合的随机对照试验。
J Clin Oncol. 2004 Jan 1;22(1):23-30. doi: 10.1200/JCO.2004.09.046. Epub 2003 Dec 9.